US Therapeutic Plasma Exchange Market Size & Share by Indication (Autoimmune Disorders, Neurological), Procedures & Patients (Multiple Sclerosis, Guillain Barre Syndrome, Glomerulonephritis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura) – Forecast 2024 to 2029

SKU: GMS-3065

Format: PDF

Overall Rating
4.5/5

OVERVIEW

The US Therapeutic Plasma Exchange Market is expected to hit USD 374.14 million by 2025, rising by 10.82% to CAGR during the forecast period. Factors such as increasing neurological disease prevalence, increasing the adoption of TPE procedures in rare disorders and increasing awareness of the increasing clinical response rate of TPE procedures in various diseases in the US are driving demand for the US Therapeutic Plasma Exchange Market.

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 1

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 2

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 3

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 4

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 5

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 6

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 7

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 8

TABLE OF CONTENT

1 US Therapeutic Plasma Exchange Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data from Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data from Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 US Therapeutic Plasma Exchange Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 US Therapeutic Plasma Exchange Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 US Therapeutic Plasma Exchange Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 US Therapeutic Plasma Exchange Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 US Therapeutic Plasma Exchange Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 US Therapeutic Plasma Exchange Market – By Procedures & Patients (Market Size – &
million/billion)
8.1 Guillain-Barré Syndrome (GBS)
8.2 Thrombotic Thrombocytopenic Purpura (TTP)
8.3 Cryoglobulinemia
8.4 Multiple Myeloma (MM)
8.5 Waldenstrom Macroglobulinemia (WM)
8.6 Myasthenia Gravis (MG)
8.7 Multiple Sclerosis (MS)
8.8 Neuromyelitis Optica (NMO)
8.9 Post-Renal Transplant Rejection
8.10 Familial Hypercholesterolemia (Homozygous)
8.11 Others

9 US Therapeutic Plasma Exchange Market – By Indication
9.1 Autoimmune Disorders
9.2 Neurological Disorders

10 US Therapeutic Plasma Exchange Market – Entropy
10.1 New product launches
10.2 M&A’s, collaborations, JVs and partnerships

11 US Therapeutic Plasma Exchange Market – Company Profile (Key Players)
11.1 Market Share, Company Revenue, Products, M&A, Developments
11.2 Haemonetics Corporation
11.3 Kawasumi Laboratories, Inc.
11.4 Baxter International Inc
11.5 Asahi Kasei Medical Co., Ltd.
11.6 Terumo BCT, Inc.
11.7 Hemacare Corporation
11.8 Fresenius Se & Co. KGAA
11.9 B. Braun Melsungen AG
11.10 Company 9
11.11 Company 10
11.12 Company 11 & more

12 US Therapeutic Plasma Exchange Market – Appendix
12.1 Sources
12.2 Abbreviations

Share

Get A Free Sample

Take a look at this complimentary sample which comprises of a variety of market data points such as trend analyses, market estimates, and forecasts. You can explore and evaluate it on your own.

Send me Free Sample

Or View Our License Options:

$3,850.00$5,850.00

Why

Industry Coverage: Global Market Studies has a broad range of industry coverage, spanning various sectors such as healthcare, technology, retail, automotive, and many others. This means that clients can rely on us to provide valuable insights into their respective industries, helping them make informed business decisions.

Our team of experts has years of experience in the market research industry, and they have honed their skills in data analysis, market forecasting, and trend analysis. They are also adept at using advanced research tools and techniques to gather and analyze data, providing clients with accurate and reliable insights.

We understand that each client has unique research needs, and we tailor our research solutions to meet their specific requirements. We work closely with our clients to understand their objectives and provide customized research solutions that address their business challenges.

We are committed to innovation and are constantly exploring new research methods and techniques to provide our clients with cutting-edge insights. This enables us to stay ahead of the curve and deliver the best possible research outcomes.

At Global Market Studies, our clients are at the center of everything we do. We pride ourselves on providing excellent customer service and support, and we are always available to address our clients’ concerns and questions.

83422+ Reports Delivered

Accurate market data is crucial to a successful business strategy. With an 85% + accuracy in all reports, makes us one of the best and most accurate firms in the world.

Need Customized Report ?Call Now

OVERVIEW

The US Therapeutic Plasma Exchange Market is expected to hit USD 374.14 million by 2025, rising by 10.82% to CAGR during the forecast period. Factors such as increasing neurological disease prevalence, increasing the adoption of TPE procedures in rare disorders and increasing awareness of the increasing clinical response rate of TPE procedures in various diseases in the US are driving demand for the US Therapeutic Plasma Exchange Market.

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 9

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 10

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 11

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 12

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 13

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 14

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 15

Us therapeutic plasma exchange market size & share by indication (autoimmune disorders, neurological), procedures & patients (multiple sclerosis, guillain barre syndrome, glomerulonephritis, myasthenia gravis, thrombotic thrombocytopenic purpura) - forecast 2024 to 2029 16

TABLE OF CONTENT

1 US Therapeutic Plasma Exchange Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data from Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data from Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 US Therapeutic Plasma Exchange Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 US Therapeutic Plasma Exchange Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 US Therapeutic Plasma Exchange Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 US Therapeutic Plasma Exchange Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 US Therapeutic Plasma Exchange Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 US Therapeutic Plasma Exchange Market – By Procedures & Patients (Market Size – &
million/billion)
8.1 Guillain-Barré Syndrome (GBS)
8.2 Thrombotic Thrombocytopenic Purpura (TTP)
8.3 Cryoglobulinemia
8.4 Multiple Myeloma (MM)
8.5 Waldenstrom Macroglobulinemia (WM)
8.6 Myasthenia Gravis (MG)
8.7 Multiple Sclerosis (MS)
8.8 Neuromyelitis Optica (NMO)
8.9 Post-Renal Transplant Rejection
8.10 Familial Hypercholesterolemia (Homozygous)
8.11 Others

9 US Therapeutic Plasma Exchange Market – By Indication
9.1 Autoimmune Disorders
9.2 Neurological Disorders

10 US Therapeutic Plasma Exchange Market – Entropy
10.1 New product launches
10.2 M&A’s, collaborations, JVs and partnerships

11 US Therapeutic Plasma Exchange Market – Company Profile (Key Players)
11.1 Market Share, Company Revenue, Products, M&A, Developments
11.2 Haemonetics Corporation
11.3 Kawasumi Laboratories, Inc.
11.4 Baxter International Inc
11.5 Asahi Kasei Medical Co., Ltd.
11.6 Terumo BCT, Inc.
11.7 Hemacare Corporation
11.8 Fresenius Se & Co. KGAA
11.9 B. Braun Melsungen AG
11.10 Company 9
11.11 Company 10
11.12 Company 11 & more

12 US Therapeutic Plasma Exchange Market – Appendix
12.1 Sources
12.2 Abbreviations

Download our eBook: Market Mastery

Unleashing revenue potential through strategic market research involves identifying untapped market opportunities, understanding consumer needs and preferences, and developing targeted strategies to capitalize on them. By leveraging data-driven insights, businesses can optimize product offerings, pricing strategies, and marketing efforts to drive revenue growth and stay ahead of competitors.

Related Research Reports